Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Merck KGaA

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck KGaA's 2013 sales performance.

Merck KGaA

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

BMS was the pathfinder for the checkpoint inhibitor market with its CTLA4 inhibitor Yervoy (ipilimumab) and PD-1 blocker Opdivo (nivolumab), However, it has since lost ground to rival Merck ... And in the meantime, Opdivo/Yervoy’s lucrative position in

Keytruda hits survival targets in first-line kidney cancer

Keytruda hits survival targets in first-line kidney cancer New data presented at ESMO congress. Merck &Co could steal the thunder of its German namesake Merck KGaA after reporting strong survival data for Keytruda in front-line renal cell carcinoma, ... MSD says Keytruda is the first anti-PD-1 drug to improve

Merck’s Bavencio joins first-line kidney cancer face-off

Merck’s Bavencio joins first-line kidney cancer face-off PD-L1 and TKI combination could challenge standard of care. Merck KGaA and Pfizer have staked a claim to the first-line renal cell carcinoma market, with data on a new ... The JAVELIN Renal 101 study reported at this week’s ESMO conference paired

Cancer disruptor F Star names next CEO

Cancer disruptor F Star names next CEO F-star has two assets in development, including its lead first-in-class, Merck KGaA-partnered candidate FS118, which works by simultaneously blocking two tumour growth promoting immune checkpoint molecules. ... The company has deals with the likes of

A look ahead to key trial readouts at ESMO

A look ahead to key trial readouts at ESMO In immuno-oncology, this year’s offering includes a first showing for data in first-line advanced renal cell carcinoma for Merck KGaA/Pfizer’s Bavencio (avelumab) in the JAVELIN Renal ... Merck &Co/MSD – already dominating non-small cell lung

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics